Deuterium imaging study for people with multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study uses a special MRI technique to look at how brain cells use energy in people with relapsing-remitting MS. It may help doctors better understand MS and guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with relapsing-remitting multiple sclerosis.
- You do not have any metal implants, a pacemaker, or other reasons that would make an MRI unsafe.
- You are not pregnant.
- You do not have diabetes or other serious brain, psychiatric, or body-wide illnesses.
- You are not participating in any other clinical trial for investigational drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether people with relapsing-remitting MS can experience symptom flare-ups (relapses) that don't show up on MRI scans. Researchers want to understand if this happens and what it means for your care.
This study looks at how certain brain changes relate to disability in people with multiple sclerosis (MS). It aims to see if measuring brain volume loss can help predict disease progression, which might help tailor treatments.
This study tests a new imaging method using a special substance called hyperpolarized 13C pyruvate to see how it can help understand multiple sclerosis. You may join if you have relapsing-remitting MS, have not used disease-modifying treatments in the past two years, and are planning to start anti-CD20 therapy.
This study uses a special PET-MRI scan to look at brain inflammation in people with relapsing-remitting multiple sclerosis (RRMS). It may help researchers understand how inflammation changes when starting a stronger MS treatment.
This study uses detailed imaging (mostly MRI) to look for patterns that may explain why multiple sclerosis can worsen. It may help researchers understand the biology behind neurodegeneration and improve future care.
This trial uses MRI scans to monitor spinal cord changes in people newly diagnosed with relapsing-remitting MS who have not yet started treatment. It aims to better understand how the disease progresses and could help guide early treatment decisions.
Hear when a new Multiple Sclerosis (MS) - Relapsing-remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.